Categoria dell'articolo: Research Article
Pubblicato online: 18 mag 2025
Pagine: 61 - 67
Ricevuto: 13 mar 2024
Accettato: 05 feb 2025
DOI: https://doi.org/10.2478/fco-2024-0006
Parole chiave
© 2024 Vito Filbert Jayalie et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Hepatocellular carcinoma (HCC) is the most common primary tumor with an increased risk of mortality and morbidity. Treatment for HCC varies based on the progressivity of disease. Radiotherapy such as stereotactic body radiotherapy (SBRT) plays an important role in the treatment of HCC. The role of radiotherapy used to be very limited to liver tumors, but recently, radiotherapy with SBRT technique has shown very promising results, both in primary liver cancer and liver metastasis. This review shows the role of radiotherapy in HCC for every stage of HCC (monotherapy, combined or bridging therapy). In liver metastasis cases, radiotherapy shows an excellent, similar, and better local control when compared with radiofrequency ablation (depending on tumor status).